Prevalence of breast fibroadenoma in healthy physical examination population in Guangdong province of China: a cross-sectional study

Abstract

ObjectiveTo provide an accurate assessment of the prevalence of breast fibroadenoma in a large population and to confirm the diagnostic accuracy of ultrasound for fibroadenoma.DesignThis was a cross-sectional survey.SettingThis research was conducted at Nanfang Hospital, Guangzhou, Guangdong, China.ParticipantsA total of 11 898 women aged 18–40 years who underwent breast screening between 1 January 2019 and 31 December 2019 were included in the fibroadenoma prevalence study. From 1 June 2019 to 31 December 2019, 342 breast lesions with pathology reports and preoperative ultrasound images were collected for diagnostic fibroadenoma testing (vs histological diagnostic testing).Primary outcome measuresPearson’s χ2 test was performed to compare the prevalence of different lesions between age groups, and descriptive statistics were used to report the clinical characteristics of fibroadenoma. For ultrasound diagnosis, fibroadenoma was defined as a well-circumscribed lesion with round or oval shape, consisting of a homogeneously hypoechoic or isoechoic solid mass, located parallel to the chest wall with a smooth margin and no posterior shadowing. Diagnostic test results for breast fibroadenoma were stratified by diagnostic type (histological vs ultrasound).ResultsOf the women aged 18–40 years, 27.6% (3285/11 898) had an ultrasound diagnosis offibroadenoma. Of these, the prevalence of fibroadenoma was stable across age groups (p=0.14) and did not differ between the left and right sides of the breast. Almost two-thirds of women presented with a single fibroadenoma, and most fibroadenomas did not exceed 1 cm in size. The sensitivity and specificity for fibroadenoma were 97.0% (95% CI for sensitivity: 93.7% to 98.8%) and 91.4% (95% CI for specificity: 85.4% to 95.5%) for ultrasonography, respectively.ConclusionsThe prevalence of fibroadenoma in South China is as high as 27.6%, and ultrasound could be used as a tool to diagnose fibroadenoma.

Fibroadenoma Mammae: Prevensi Berdasarkan Karakteristik dan Faktor Risiko

“…2 Prevalensi di China Selatan dilaporkan sebesar 27,6%. 3 Data terbaru tentang FAM di Indonesia 5-10 tahun terakhir masih terbatas, namun laporan yayasan kanker memperkirakan ada 100 orang terkena tumor jinak payudara selama pertengahan tahun 2011. 3,4 Fibroadenoma mammae dapat didiagnosis melalui klinis pemeriksaan payudara, ultrasonografi payudara dan fine-needle aspirate cytology.…”

“…3 Data terbaru tentang FAM di Indonesia 5-10 tahun terakhir masih terbatas, namun laporan yayasan kanker memperkirakan ada 100 orang terkena tumor jinak payudara selama pertengahan tahun 2011. 3,4 Fibroadenoma mammae dapat didiagnosis melalui klinis pemeriksaan payudara, ultrasonografi payudara dan fine-needle aspirate cytology. 3 Penelitian terkini menyarankan bahwa ultrasound modern adalah alat yang andal untuk melakukan diagnosis fibroadenoma.…”

Double blind randomized controlled trial of efficacy of ormeloxifene for the treatment of fibroadenoma (The FIBROCENT study)

“…The reported incidence is 20%-30% during a woman's lifetime. [1][2][3] The treatment of fibroadenomas has rapidly evolved over the years. In the past, surgical excision was the standard practice due to concern regarding cancer, impact on psychosocial well-being and/or growth.…”

“…Fibroadenoma is a common malady in young women affecting their quality of life. The reported incidence is 20%–30% during a woman's lifetime 1–3 . The treatment of fibroadenomas has rapidly evolved over the years.…”

Understanding Fibroadenoma of the Breast: A Comprehensive Review of Pre-operative and Post-operative Clinicopathological Correlations

“…The incidence and prevalence of fibroadenoma vary depending on the age group and population. The prevalence of breast fibroadenoma in women aged 18-40 years in a study conducted in Guangdong province of China was 27.6% [ 2 ]. The incidence of fibroadenoma decreases with age, and it is generally found before 30 years of age in females in the general population [ 1 ].…”